article thumbnail

Cargo agrees to Concentra buyout after trial setback, layoffs

BioPharma Drive: Drug Pricing

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

This absence of objective measures contributes to the variability in patient response to treatments, complicating efforts to produce standardised therapies. Moreover, regulatory pathways also change considerably based on the type of therapy – and guidance is sparse.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

J&J’s Dual-Target CAR T-Cell Therapy Shows Promise in Large B-Cell Lymphoma

The Pharma Data

Standard single-target CD19-directed CAR T-cell therapies typically enable long-term remissions in roughly 40% of patients, emphasizing a significant unmet need for new and more effective treatment strategies. Among patients who had previously undergone two or more lines of therapy (n = 12), the ORR was 92% and the CRR was 75%.

article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.

article thumbnail

Altasciences at ASGCT 2025: An Open Forum for All Things Gene and Cell Therapy | By Kaylyn Koenig

Alta Sciences

Altasciences at ASGCT 2025: An Open Forum for All Things Gene and Cell Therapy | By Kaylyn Koenig aasimakopoulos Thu, 07/10/2025 - 08:00 I recently returned from attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. WHO WAS AT ASGCT 2025?

article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

Patient recruitment The ability to increase diverse patient enrollment has improved , primarily among large sponsors, with 42% seeing improvement compared to 29% in 2023. Growth of DCTs is expected to continue, and in two years, respondents expect over 90% of their trials to be using decentralized elements, similar to 2023 estimates.

article thumbnail

Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer

The Pharma Data

The investigational ADC is built using Daiichi Sankyo’s proprietary DXd technology and represents one of the newest generation of targeted cancer therapies. It will enroll patients with mCRPC who have experienced disease progression during or after ARPI therapy.